vs
BALCHEM CORP（BCPC）与慧与（CITR）财务数据对比。点击上方公司名可切换其他公司
BALCHEM CORP的季度营收约是慧与的914.7倍（$263.6M vs $288.2K）。BALCHEM CORP净利率更高（14.9% vs -2751.2%，领先2766.1%）。慧与同比增速更快（169.3% vs 9.8%）。过去两年慧与的营收复合增速更高（28.4% vs 4.9%）
Balchem Corp是一家全球特种化学品与营养原料供应商，核心业务覆盖人类营养、动物保健、制药、工业应用四大领域，为北美、欧洲、亚太等地区的客户提供定制化专用原料产品。
慧与（HPE）是一家总部位于美国得克萨斯州斯普林的跨国信息技术企业，主打面向企业级客户的业务，业务领域涵盖服务器、存储、网络、容器化软件以及相关咨询与支持服务，在2018年财富美国500强总营收排名中位列第107名。
BCPC vs CITR — 直观对比
营收规模更大
BCPC
是对方的914.7倍
$288.2K
营收增速更快
CITR
高出159.4%
9.8%
净利率更高
BCPC
高出2766.1%
-2751.2%
两年增速更快
CITR
近两年复合增速
4.9%
损益表 — Q4 2025 vs Q3 2025
| 指标 | | |
|---|---|---|
| 营收 | $263.6M | $288.2K |
| 净利润 | $39.2M | $-7.9M |
| 毛利率 | 35.6% | -99.7% |
| 营业利润率 | 19.8% | -1470.3% |
| 净利率 | 14.9% | -2751.2% |
| 营收同比 | 9.8% | 169.3% |
| 净利润同比 | 16.8% | -1110.1% |
| 每股收益（稀释后） | $1.21 | $-0.59 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BCPCCITR
| Q4 25 | $263.6M | — | ||
| Q3 25 | $267.6M | $288.2K | ||
| Q2 25 | $255.5M | $687.6K | ||
| Q1 25 | $250.5M | $969.4K | ||
| Q4 24 | $240.0M | — | ||
| Q3 24 | $239.9M | $107.0K | ||
| Q2 24 | $234.1M | $198.7K | ||
| Q1 24 | $239.7M | $433.0K |
净利润BCPCCITR
| Q4 25 | $39.2M | — | ||
| Q3 25 | $40.3M | $-7.9M | ||
| Q2 25 | $38.3M | $-11.9M | ||
| Q1 25 | $37.1M | $-10.9M | ||
| Q4 24 | $33.6M | — | ||
| Q3 24 | $33.8M | $-655.2K | ||
| Q2 24 | $32.1M | $-907.4K | ||
| Q1 24 | $29.0M | $-3.5M |
毛利率BCPCCITR
| Q4 25 | 35.6% | — | ||
| Q3 25 | 35.7% | -99.7% | ||
| Q2 25 | 36.4% | 46.0% | ||
| Q1 25 | 35.2% | 42.5% | ||
| Q4 24 | 36.0% | — | ||
| Q3 24 | 35.6% | -30.0% | ||
| Q2 24 | 35.5% | 48.6% | ||
| Q1 24 | 34.0% | 79.2% |
营业利润率BCPCCITR
| Q4 25 | 19.8% | — | ||
| Q3 25 | 20.4% | -1470.3% | ||
| Q2 25 | 20.1% | -438.8% | ||
| Q1 25 | 20.4% | -356.8% | ||
| Q4 24 | 19.8% | — | ||
| Q3 24 | 20.0% | -524.4% | ||
| Q2 24 | 19.6% | -456.7% | ||
| Q1 24 | 17.4% | -608.9% |
净利率BCPCCITR
| Q4 25 | 14.9% | — | ||
| Q3 25 | 15.1% | -2751.2% | ||
| Q2 25 | 15.0% | -1731.1% | ||
| Q1 25 | 14.8% | -1124.8% | ||
| Q4 24 | 14.0% | — | ||
| Q3 24 | 14.1% | -612.1% | ||
| Q2 24 | 13.7% | -456.7% | ||
| Q1 24 | 12.1% | -812.8% |
每股收益（稀释后）BCPCCITR
| Q4 25 | $1.21 | — | ||
| Q3 25 | $1.24 | $-0.59 | ||
| Q2 25 | $1.17 | $-0.19 | ||
| Q1 25 | $1.13 | $-0.23 | ||
| Q4 24 | $1.03 | — | ||
| Q3 24 | $1.03 | $-0.11 | ||
| Q2 24 | $0.98 | $-0.02 | ||
| Q1 24 | $0.89 | $-0.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $74.6M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.3B | $8.5M |
| 总资产 | $1.7B | $12.3M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BCPCCITR
| Q4 25 | $74.6M | — | ||
| Q3 25 | $65.1M | — | ||
| Q2 25 | $65.4M | — | ||
| Q1 25 | $49.9M | — | ||
| Q4 24 | $49.5M | — | ||
| Q3 24 | $73.7M | — | ||
| Q2 24 | $63.7M | — | ||
| Q1 24 | $60.3M | — |
股东权益BCPCCITR
| Q4 25 | $1.3B | — | ||
| Q3 25 | $1.3B | $8.5M | ||
| Q2 25 | $1.3B | $2.2M | ||
| Q1 25 | $1.2B | $4.1M | ||
| Q4 24 | $1.1B | — | ||
| Q3 24 | $1.2B | $2.8M | ||
| Q2 24 | $1.1B | $3.2M | ||
| Q1 24 | $1.1B | $3.8M |
总资产BCPCCITR
| Q4 25 | $1.7B | — | ||
| Q3 25 | $1.7B | $12.3M | ||
| Q2 25 | $1.7B | $8.7M | ||
| Q1 25 | $1.6B | $9.1M | ||
| Q4 24 | $1.6B | — | ||
| Q3 24 | $1.6B | $4.9M | ||
| Q2 24 | $1.6B | $5.4M | ||
| Q1 24 | $1.6B | $5.3M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $67.3M | $-1.5M |
| 自由现金流经营现金流 - 资本支出 | — | $-1.5M |
| 自由现金流率自由现金流/营收 | — | -525.6% |
| 资本支出强度资本支出/营收 | — | 18.7% |
| 现金转化率经营现金流/净利润 | 1.72× | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流BCPCCITR
| Q4 25 | $67.3M | — | ||
| Q3 25 | $65.6M | $-1.5M | ||
| Q2 25 | $47.3M | $-1.2M | ||
| Q1 25 | $36.5M | $-713.9K | ||
| Q4 24 | $52.3M | — | ||
| Q3 24 | $51.3M | $-551.3K | ||
| Q2 24 | $45.0M | $-424.9K | ||
| Q1 24 | $33.4M | $-343.7K |
自由现金流BCPCCITR
| Q4 25 | — | — | ||
| Q3 25 | — | $-1.5M | ||
| Q2 25 | — | $-1.4M | ||
| Q1 25 | — | $-740.9K | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
自由现金流率BCPCCITR
| Q4 25 | — | — | ||
| Q3 25 | — | -525.6% | ||
| Q2 25 | — | -196.7% | ||
| Q1 25 | — | -76.4% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
资本支出强度BCPCCITR
| Q4 25 | — | — | ||
| Q3 25 | — | 18.7% | ||
| Q2 25 | — | 20.5% | ||
| Q1 25 | — | 2.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 0.0% | ||
| Q1 24 | — | 0.0% |
现金转化率BCPCCITR
| Q4 25 | 1.72× | — | ||
| Q3 25 | 1.63× | — | ||
| Q2 25 | 1.23× | — | ||
| Q1 25 | 0.98× | — | ||
| Q4 24 | 1.56× | — | ||
| Q3 24 | 1.52× | — | ||
| Q2 24 | 1.40× | — | ||
| Q1 24 | 1.15× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BCPC
| Human Nutrition And Health | $166.1M | 63% |
| Animal Nutrition And Health | $61.2M | 23% |
| Specialty Products | $34.8M | 13% |
CITR
暂无分部数据
